in the absence of a submission from the holder of the marketing authorisation:
imipenem/cilastatin/relabactam (Recarbrio®) is not recommended for use within NHSScotland.
Indication under review: For treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice618KB (PDF)
- Medicine name:
- imipenem/cilastatin/relabactam (Recarbrio)
- SMC ID:
For treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published
- 12 July 2021